[
  {
    "ts": null,
    "headline": "Why Regeneron (REGN) Stock Is Down Today",
    "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.8% in the afternoon session after a court ruling in Australia dealt a blow to the company's efforts to block a competing version of its blockbuster eye drug, EYLEA.",
    "url": "https://finnhub.io/api/news?id=7fd0fe3a0f427ebb463de3a25821c2b25de59c7fd054a9ff76070fc7436ef289",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758655560,
      "headline": "Why Regeneron (REGN) Stock Is Down Today",
      "id": 136855647,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Shares of biotech company Regeneron (NASDAQ:REGN) fell 4.8% in the afternoon session after a court ruling in Australia dealt a blow to the company's efforts to block a competing version of its blockbuster eye drug, EYLEA.",
      "url": "https://finnhub.io/api/news?id=7fd0fe3a0f427ebb463de3a25821c2b25de59c7fd054a9ff76070fc7436ef289"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron: Looking For Green Shoots Of Growth On Top Of Heartwood Franchises",
    "summary": "Discover why Regeneron (REGN) is a top investment pick with strong Dupixent growth, a robust pipeline, and lasting potential. Click here to read my analysis.",
    "url": "https://finnhub.io/api/news?id=9c6a694d51ba2bc55414e7d231c82b3207cc9d95ac434aee6de1db228978ea62",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758652145,
      "headline": "Regeneron: Looking For Green Shoots Of Growth On Top Of Heartwood Franchises",
      "id": 136856707,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2167860481/image_2167860481.jpg?io=getty-c-w1536",
      "related": "REGN",
      "source": "SeekingAlpha",
      "summary": "Discover why Regeneron (REGN) is a top investment pick with strong Dupixent growth, a robust pipeline, and lasting potential. Click here to read my analysis.",
      "url": "https://finnhub.io/api/news?id=9c6a694d51ba2bc55414e7d231c82b3207cc9d95ac434aee6de1db228978ea62"
    }
  },
  {
    "ts": null,
    "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=4e4180c58d12e82c9f53084102c9128af878c0afbf9e332c3c43fde2c95b8b58",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758645000,
      "headline": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "id": 136872925,
      "image": "",
      "related": "REGN",
      "source": "MarketWatch",
      "summary": "Regeneron Pharmaceuticals Inc. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=4e4180c58d12e82c9f53084102c9128af878c0afbf9e332c3c43fde2c95b8b58"
    }
  },
  {
    "ts": null,
    "headline": "US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall",
    "summary": "(Reuters) -Scholar Rock said on Tuesday the U.S. health regulator has declined to approve its drug for a rare neuromuscular disease citing issues at a third-party manufacturing facility, sending the company's shares down 12% in premarket trading.  Scholar Rock is banking on apitegromab to drive its growth and profitability.  The drug is being tested as a treatment for spinal muscular atrophy and muscle preservation in obesity.",
    "url": "https://finnhub.io/api/news?id=fd6692f2728488f6f590c8e24e5316dee54f14a6b4c057bb3a38941fbf796460",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758625910,
      "headline": "US FDA declines to approve Scholar Rock's muscle weakness drug; shares fall",
      "id": 136851366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "(Reuters) -Scholar Rock said on Tuesday the U.S. health regulator has declined to approve its drug for a rare neuromuscular disease citing issues at a third-party manufacturing facility, sending the company's shares down 12% in premarket trading.  Scholar Rock is banking on apitegromab to drive its growth and profitability.  The drug is being tested as a treatment for spinal muscular atrophy and muscle preservation in obesity.",
      "url": "https://finnhub.io/api/news?id=fd6692f2728488f6f590c8e24e5316dee54f14a6b4c057bb3a38941fbf796460"
    }
  }
]